title: Late progression after sirolimus-eluting stent implantation for de novo lesions--comparison with bare metal stent implantation.
abstract: BACKGROUND
  In previous studies, the minimal luminal diameter (MLD) of lesions treated with a bare metal stent (BMS) was shown to improve from 6 months to 3 years. However, the long-term response to a sirolimus-eluting stent (SES) implantation remains unclear.
  
  
  RESULTS
  To evaluate 6-month, 12-month and 3-year outcomes, clinical and angiographic follow-up data were analyzed for 367 consecutive patients (506 de novo lesions) who underwent successful SES implantation compared to follow-up data for 617 consecutive patients (802 de novo lesions) who underwent BMS implantation. Clinical follow-up information was obtained for 363 SES-treated patients (98.9%) and 581 BMS-treated patients (94.2%) at 1 year, and 334 SES-treated patients (91.0%) and 566 BMS-treated patients (91.7%) at 3 years. At 3 years, there were no significant differences in the cumulative cardiac death and myocardial infarction. Target lesion revascularization (TLR) rates were significantly higher in BMS-treated patients than in SES-treated patients. In BMS-treated patients, most TLR was performed within 450 days, however, after 450 days, the TLR rate was significantly lower than that for the SES-treated patients. In quantitative coronary angiographic data, among lesions that required no revascularization at the initial 12-month follow up, MLD increased significantly from the 12-month to the 3-year follow-up angiography in BMS-treated lesions. However, MLD decreased significantly in SES-treated lesions.
  
  
  CONCLUSIONS
  From a 12-month follow-up to a 3-year follow-up, stenosis in BMS-treated lesions regressed, but stenosis in SES-treated lesions progressed. And late TLR was more frequently required in the SES-treated patients.
authors.affiliation: Department of Cardiology, Matsue Red Cross Hospital, Matsue, Japan. nobucode.0317@kfd.biglobe.ne.jp
authors.forename: Nobuo
authors.initials: N
authors.lastname: Shiode
authors.forename: Kinya
authors.initials: K
authors.lastname: Shirota
authors.forename: Fumiyo
authors.initials: F
authors.lastname: Tsunoda
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Kato
authors.forename: Mai
authors.initials: M
authors.lastname: Fujiwara
authors.forename: Asao
authors.initials: A
authors.lastname: Mimura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003251:Constriction, Pathologic / Q000209:etiology; D003643:Death; D018450:Disease Progression; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D020123:Sirolimus